AstraZeneca and insitro sign AI drug deal
AstraZeneca has partnered with insitro in a 40 million dollar deal to develop new liver and heart treatments. The collaboration will use artificial intelligence to identify causal disease biology.
Xurve View
Insights:
Xurve View
AstraZeneca will pay $40 million upfront in an artificial intelligence drug discovery deal with insitro targeting liver and heart diseases. The United Kingdom drugmaker is partnering with the California-based biotech firm to tackle conditions that have long lacked effective therapies. The agreement includes up to $1.46 billion in potential development and commercial milestones, alongside royalties on future sales.
